13F reference period
Q2 2026
Security Snapshot
Eloxx Pharmaceuticals, Inc. - Common Stock, $0.01 par value per share (ELOX) Institutional Ownership
CUSIP: 29014R301
13F Institutional Holders and Ownership History from Q2 2026 to Q3 2026
Institutions Reporting
22
Shares (Excl. Options)
2.5M
Full value: 2,499,714 · shares · 30 Jun 2026Price
$13.88
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.01 par value per share
- Symbol
- ELOX on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,499,714
- Total 13F value
- $34,695,672
- Portfolio coverage rank
- 0%
- Share change
- +2,499,714
- Value change
- +$34,695,672
- Number of holders
- 22
- Shares outstanding
- 4,076,626
- SEC-reported price per share
- $15.38
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- ELOX - Eloxx Pharmaceuticals, Inc. - Common Stock, $0.01 par value per share is tracked under CUSIP 29014R301.
- 22 institutions reported positions in Q2 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- The headline uses Q2 2026 reported holdings.
- Quarter-over-quarter comparison is unavailable because the immediately preceding quarter is missing.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 22 institutions filings for Q2 2026.
Security key
29014R301
13F reference period
Q2 2026
13F holders
22
13D/G owners
6
CIK / CUSIP context first
Open Q2 2026 holders
ELOX full holder history
Eloxx Pharmaceuticals, Inc. SEC filings
Eloxx Pharmaceuticals, Inc. company facts
Eloxx Pharmaceuticals, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 29014R301:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ELOX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Domicilium Real Estate Fund III LP | 20% | +302% | 854,973 | +3542% | Domicilium Capital Partners LLC | 05 Jun 2026 | ||
| Invus Global Management, LLC | 10% | 403,586 | Raymond Debbane | 09 Jun 2026 | ||||
| EcoR1 Capital, LLC | 9.9% | 403,586 | EcoR1 Capital, LLC | 09 Jun 2026 | ||||
| Samsara BioCapital, L.P. | 9.9% | $4,580,701 | 403,586 | Srinivas Akkaraju | 10 Jun 2026 | |||
| Stonepine Capital Management, LLC | 9.9% | 403,228 | Stonepine Capital Management, LLC | 09 Jun 2026 | ||||
| Nantahala Capital Management, LLC | 9.9% | $4,540,000 | 400,000 | Nantahala Capital Management, LLC | 30 Jun 2026 |
As of 30 Jun 2026,
22
institutional investors reported holding
shares of
Eloxx Pharmaceuticals, Inc. - Common Stock, $0.01 par value per share (ELOX).
This represents
61%
of the company’s total
outstanding shares.
2.5M
Full value: 2,499,714 · shares · 30 Jun 20264.08M
Full value: 4,076,626 · shares · Stored outstanding share count13F concentration
Top 22 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
61%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 9.8% | 400,000 | 0.28% | $5,552,000 | |
| Aberdeen Group plc | 9.8% | 400,000 | 0.01% | $5,552,000 | |
| Siren, L.L.C. | 9.8% | 400,000 | 0.11% | $5,552,000 | |
| SAMSARA BIOCAPITAL, LLC | 9.8% | 400,000 | 0.46% | $5,552,000 | |
| Nantahala Capital Management, LLC | 9.8% | 400,000 | 0.34% | $5,552,000 | |
| Stonepine Capital Management, LLC | 9.7% | 397,160 | 4.2% | $5,512,581 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.9% | 78,680 | 0% | $1,092,078 | |
| VANGUARD FIDUCIARY TRUST CO | 0.26% | 10,602 | 0% | $147,156 | |
| SEVEN GRAND MANAGERS, LLC | 0.25% | 10,000 | 0.01% | $138,800 | |
| MORGAN STANLEY | 0.04% | 1,544 | 0% | $21,431 | |
| Vanguard Global Advisers, LLC | 0.02% | 718 | 0% | $9,966 | |
| UBS Group AG | 0.02% | 637 | 0% | $8,842 | |
| WELLS FARGO & COMPANY/MN | 0% | 126 | 0% | $1,749 | |
| ROYAL BANK OF CANADA | 0% | 98 | 0% | $1,000 | |
| Pioneer Family Office, LLC | 0% | 96 | 0% | $1,332 | |
| Altshuler Shaham Ltd | 0% | 25 | 0% | $347 | |
| BARCLAYS PLC | 0% | 12 | 0% | $167 | |
| Towne Trust Company, N.A | 0% | 5 | 0% | $69 | |
| Activest Wealth Management | 0% | 4 | 0% | $56 | |
| CITIGROUP INC | 0% | 4 | 0% | $56 | |
| SBI Securities Co., Ltd. | 0% | 2 | 0% | $28 | |
| Point Nemo Capital, LLC | 0% | 1 | 0% | $14 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
2
Headline period
Q2 2026
Rows shown
1-2 of 2